ADA: EMPA-REG Continues To Impress With More Data For Lilly/Boehringer's Jardiance
Executive Summary
Eli Lilly & Co. and Boehringer Ingelheim GMBH have once again excited doctors with further analysis presented at the American Diabetes Association's meeting for Jardiance (empagliflozin) from the EMPA-REG cardiovascular outcomes study – this time showing benefits for kidney protection.
You may also be interested in...
Lilly's Growth In Diabetes Gives It Market Leading Position
The diabetes giant has overtaken competition in key areas due to successes across several classes and strong data.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.